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Summary 
Platelet-endothelial  cell adhesion molecule-1  (PECAM-1,  CD31)  plays an active role in the 
process of leukocyte migration through cultured endothelial cells in vitro and anti-PECAM-1 
antibodies (Abs) inhibit accumulation ofleukocytes into sites of inflammation in vivo. Despite 
the latter, it is still  not clear at which stage of leukocyte emigration in vivo PECAM-1  is in- 
volved. To address this point directly, we studied the effect of an anti-PECAM-1  Ab, recog- 
nizing rat PECAM-1, on leukocyte responses within rat mesenteric microvessels using intravital 
microscopy. In mesenteric preparations activated by interleukin  (IL)-113, the  anti-PECAM-1 
Ab had no significant effect on the rolling or adhesion ofleukocytes, but inhibited their migra- 
tion into the surrounding extravascular tissue in a dose-dependent manner. Although in some 
vessel segments these leukocytes had come to a halt within the vascular lumen, often the leuko- 
cytes appeared to be trapped within the vessel wall. Analysis of these sections by electron mi- 
croscopy revealed that the leukocytes had passed through endothelial cell junctions but not the 
basement membrane. In contrast to the effect of the Ab in mesenteric preparations treated with 
IL-113,  leukocyte  extravasation  induced  by  topical  or  intraperitoneal  administration  of the 
chemotactic  peptide  formyl-methionyl-leucyl-phenylalanine was  not  inhibited  by the  anti- 
PECAM-1 Ab. These results directly demonstrate a role for PECAM-1 in leukocyte extravasa- 
tion in vivo and indicate that this involvement is selective for leukocyte extravasation elicited 
by certain inflammatory mediators.  Further,  our findings provide the first in vivo indication 
that PECAM-1 may have an important role in triggering the passage of leukocytes through the 
perivascular basement membrane. 
T 
he migration ofleukocytes from the microvasculature 
into the tissue is an essential part of an inflammatory 
reaction. This response is mediated by the adhesive interac- 
tion  of leukocytes with  venular  endothelial  cells  and  ap- 
pears to involve multiple sequential steps (1). The initial in- 
teraction appears to be that of a weak reversible adhesion 
between  leukocytes  and  endothelial  cells  resulting  in  the 
rolling of leukocytes along the venular wall. There is now 
much in vitro and in vivo evidence demonstrating the im- 
portance of the selectin family of adhesion molecules in this 
phase of the  response  (2),  although  more recently,  mem- 
bers of the integrin family have also been implicated in the 
phenomenon  of leukocyte roiling  (3-5).  Rolling cells  can 
then become activated by chemotactic stimuli  expressed/ 
bound on the surface of endothelial cells  or in solution at 
the site of inflammation. The interaction of activated leu- 
kocyte adhesion  molecules,  primarily members of the  [31 
and [32 integrins, with their endothelial cell ligands, such as 
intercellular adhesion molecule-1  (ICAM-1) 1 ICAM-2, or 
vascular cell adhesion molecule-1  (VCAM-1)  enables roll- 
ing leukocytes to  establish a firm adhesive bond with the 
vascular endothelium.  Interestingly, the firm attachment of 
leukocytes to venular endothelial cells itself appears to trig- 
1Abbreviations used in this paper: ICAM-1, intercellular adhesion molecule-i; 
PAF, platelet-activating  factor; PECAM-1, platelet-endothelial cell adhe- 
sion molecule-i; VCAM-1, vascular cell adhesion molecule-l. 
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and perhaps the endothelial cells, that may mediate the flat- 
tening  of the  leukocytes  over  the  endothelium,  enabling 
them to locate and penetrate interendothelial cell  junctions. 
Despite the increasing number of in vivo studies investigat- 
ing the molecular interactions involved in  the  rolling and 
firm adhesion ofleukocytes, there is much less information 
regarding the in vivo mechanisms mediating the passage of 
leukocytes across the vessel wall. 
Platelet-endothelial cell adhesion molecule-1 (PECAM-1), 
a member of the Ig superfamily, is a  130-kD  glycoprotein 
expressed  on  the  cell surface  of platelets, leukocytes, and 
endothelial cells. The expression of PECAM-1  on cultured 
endothelial cells is concentrated at cell-cell  junctions (7, 8), 
and there is now strong evidence demonstrating a role for 
this molecule in the passage of neutrophils and rnonocytes 
across resting and cytokine-activated endothelial monolay- 
ers in vitro  (9).  In three different in vivo models of acute 
inflammation, neutrophil accumulation into inflamed peri- 
toneum of rats, neutrophil accumulation into airways after 
local  deposition  of IgG  immune  complexes  in  rat  lungs, 
and neutrophil accumulation induced by intradermal TNF-cl 
into human  skin grafts transplanted onto immunodeficient 
mice, Vaporciyan et al.  (10)  found that an anti-PECAM-1 
Ab  inhibited the  emigration  of neutrophils.  Similarly, an 
anti-routine  PECAM-1  antibody inhibited thioglycollate- 
induced  leukocyte  accumulation  into  mouse  peritoneum 
(11).  Despite these findings, the precise role of PECAM-1 
in  leukocyte  recruitment  in  vivo  is  still not  fully under- 
stood. The  aim of the present study was to investigate di- 
rectly by  intravital  and  electron  microscopy  the  stage  of 
leukocyte  emigration  at  which  PECAM-1  was  involved, 
and thus  determine more precisely the role of PECAM-1 
in leukocyte extravasation in vivo. 
Materials  and Methods 
Animals.  Male Spragne-Dawley rats  (250-300  g)  were pur- 
chased from Harlan-Olac (Bicester, Oxfordshire, UK). 
Materials.  Pentobarbitone  sodium  (Sagatal,  60  mg/ml)  was 
purchased from Rhone Merieux Ltd. (Harlow, Essex, UK). Hyp- 
norm  (0.315  mg/ml fentanyl citrate and  10  mg/ml fluanisone) 
was  from Janssen Pharmaceutical Ltd.  (Grove, UK).  FMLP and 
rabbit  IgG,  purified  from  normal  serum,  were  from  Sigma 
Chemical Co. (Poole, Dorset, UK). Recombinant rat IL-113 was 
a gift from Dr. K. Vosbeck (Ciba-Geigy Ltd., Basel, Switzerland). 
The  anti-PECAM-I  antibody was a rabbit polyclonal antibody 
generated  by  immunization  with  purified  human  PECAM-1. 
This Ab cross-reacts with rat PECAM-1  as previously described 
(10). Purified Ab from the preimmune serum was used as con- 
trol Ab in some experiments. Both antibodies were prepared by 
protein G-Sepharose chromatography. A  murine anti-rat MHC 
class I mAb from Harlan Sera-Lab (Crawley Down, Sussex, UK) 
was  used as a second control antibody. All antibodies were as- 
sayed for  endotoxin  levels using  a  Limulus  Amebocyte Lysate 
[QCL  1000]  kit,  from  BioWhittaker Inc.  (Walkersville, MD). 
The  antibodies used in the study had endotoxin levels of <3.5 
ng/ml.  This meant that the rats were injected with <0.8 ng of 
endotoxin. Rats injected with the anti-PECAM-1 Ab were in- 
jected with <0.2 ng of endotoxin and the rats injected with the 
purified rabbit IgG were injected with <0.8 ng of endotoxin. 
Intravital Microscopy.  Animals were prepared for intravital mi- 
croscopy as previously described (12).  Briefly, rats were sedated 
with an intramuscular injection of Hypnorm (0.2 ml/rat) and in- 
jected intraperitoneally with either 5 ml of sterile saline, 5 ml of 
sterile saline containing 10 ng IL-113, or 5 ml of sterile saline con- 
taining 220 ng of FMLP. Animals were pretreated, 15 min before 
IL-113 or FMLP administration, with either anti-PECAM-1 anti- 
body (1  or 5 mg/kg), control rabbit IgG (in some experiments, 
purified from preimmune serum), or an anti-MHC class I mAb, 
injected via a lateral tail vein. 3.5 h later, the rats were resedated 
intramuscularly with Hypnorm (0.1 rnl) and anesthetized intrave- 
nously with Sagatal (20 mg/kg). Anesthesia was maintained intra- 
venously with 20 mg/kg/h of Sagatal. Animals were then placed 
on a heated stage (37~  and a  1-2-cm midline abdominal inci- 
sion was made to expose the small intestine. A segment of the in- 
testine was carefully exteriorized and placed over a  transparent 
circular plastic mount  and pinned in place. The  exposed tissue 
was continuously superfused with sterile Tyrode solution main- 
tained at 37~  and gassed with 5% CO2 in air. The whole prepa- 
ration  was  mounted  onto  the  stage  of a  Diaplan  microscope 
(Leitz, Germany) and the mesenteric microcirculation was viewed 
using  high  magnification  water-dipping  objectives.  A  camera 
(model WV CL702  CCD;  Panasonic), mounted on the micro- 
scope relayed the image onto a color monitor (Sony Trinitron) 
and the images were recorded using an S-VHS video cassette re- 
corder  (model HP,-54700EK;  JVC)  and  a  color video  printer 
(model CVP-M3E,  Sony). To  determine the effect of the anti- 
bodies  on  circulating leukocyte numbers,  blood  samples were 
taken from the rats before and 4 h after antibody treatment. 
In each animal, leukocyte responses were measured in three to 
five randomly selected postcapillary venules ranging between 20 
and 35 txm in diameter and of at least 400 p~m in length. In each 
vessel,  three parameters were measured: leukocyte rolling, adhe- 
sion, and extravasation, as previously described (12). Rolling leu- 
kocytes were defined as cells visibly moving along the endothe- 
lium.  For each  vessel,  the  number  of rolling cells  per  minute 
passing a reference point was counted over a 4-rain time period. 
Adherent leukocytes were defined as cells that remained station- 
ary within the vascular lumen for a period of at least 30 s. Adher- 
ent cells were counted in at least four consecutive 100-btm vessel 
segments for every vessel. Leukocyte emigration from the micro- 
circulation into the tissue was quantified by counting the number 
of cells that had emigrated out of the vessel up to 50, 50-100, and 
100-150  ~zm away from the vessel wall in parallel with 100-lzm 
vessel segments. At least four readings were taken for each vessel 
at different distances from the vessel wall. 
In a second series  of experiments designed to investigate the 
effect of the  anti-PECAM-1  Ab  on  rapid leukocyte responses 
elicited by topical FMLP, rats were prepared for intravital micros- 
copy as described above; basal readings of rolling, adhesion, and 
extravasation were recorded for a period of 15 rain in one venule 
of 20-35  p~m  in  diameter.  The  anti-PECAM-1  antibody or a 
control antibody, both at 5 rng/kg, was then administered intra- 
venously; readings of the three leukocyte responses were  taken 
for a further 15-rain period. The exteriorized mesentery was then 
superfused with FMLP (final concentration of 10 -7 M, in Tyrode 
solution maintained at 37~  for up to 30 rain and measurements 
of leukocyte rolling, adhesion, and  extravasation were  taken  at 
different time points throughout the duration of the experiment. 
Preparation of Mesenteric Tissues for Electron Microscopy.  At the end 
of intravital microscopy studies, the animal was killed by a lethal 
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Figure  1.  Effect  of anti-PECAM-1  Ab  on 
IL-l~-induced  leukocyte  responses  within  rat 
mesenteric microvessels, kats were  treated in- 
traperitoneally with saline (U]) or  10 ng IL-1[3 
(I).  In  further  groups  of animals,  rats  were 
treated with a control Ab (rabbit IgG, 5 mg/kg 
i.v., []) or the anti-PECAM-1  Ab (1 or 5 nag/ 
kg i.v.,  k~),  15 min before the i.p.  administra- 
tion of IL-113.  4  h  later,  the mesenteric tissue 
was exteriorized and the responses of leukocyte 
rolling (A), adhesion (B), and extravasation (C) 
quantified. Results are mean +  SEM for n  =  5 
animals. A significant difference between saline- 
and  IL-113-  or  IL-113  +  control  Ab-treated 
animals is shown by (*)P <0.05.  A  significant 
difference  between  IL-I~  +  control  Ab  and 
IL-I~  +  anti-PECAM-1  Ab  is  shown  by 
(+)P <0.01. 
overdose  of sodium  pentobarbitone  and the  exteriorized  mesen- 
tery superfused  with 2.5%  glutaraldehyde  (in 0.05  M  sodium  ca- 
codylate buffer, pH 7.2) for 10 min. The area containing the ves- 
sels  of  interest  was  then  removed  and  further  fixed  in  2.5% 
glutaraldehyde  overnight.  After washing in cacodylate buffer,  the 
mesenteric section was postfixed in 1% osmium tetroxide for 1 h, 
dehydrated in a series of solutions with increasing methanol con- 
centrations in water, and transferred to propylene oxide, after which 
231  Wakelin et al. the section was embedded horizontally in araldite. Smaller blocks 
containing the vessels of interest were cut out and mounted verti- 
cally for sectioning. Sections of vessels (1-lxm-thick) were stained 
with alkaline toluidine blue and viewed by light microscopy. For 
electron microscopy, ultrathin sections were stained with uranyl 
acetate and lead citrate. Mesenteric sections from control Ab- and 
anti-PECAM-l-treated animals were prepared for electron mi- 
croscopy in parallel. 
Statistics.  Data are expressed as the mean  --- SEM for n ani- 
mals and analyzed using the Mann-Whitney nonparametric test, 
or Student's t test when appropriate, for the comparison of two 
samples. P values of <0.05 were considered statistically significant. 
Results 
Effect  of Anti-PECAM-1  Ab on Leukocyte Responses  in IL- 
l,if-activated Microvessels.  In  rats  injected intraperitoneally 
with  saline,  there  was  a  basal  level  of leukocyte  rolling, 
ranging between  16  and  34  leukocytes per minute  (25  + 
3.0,  mean  +  SEM,  n  =  5), a low level of leukocyte adhe- 
sion within  the  venules  and  a  small number  of emigrated 
leukocytes in the extravascular tissue (Fig.  1 and Fig. 2  A). 
In animals treated with IL-113 (10 ng i.p. for 4  h),  all three 
leukocyte responses  measured  were  significantly increased 
(P  <0.05,  n  =  5),  with  leukocyte rolling increasing to  a 
range between 37 and 57 leukocytes per minute (Fig. 1 and 
Fig. 2  B). IL-113 increased the number of cells that had em- 
igrated into the surrounding tissue at all three measurement 
points studied (Fig. 3). 
Pretreatment of rats with control antibody (purified rab- 
bit IgG, 5  mg/kg i.v.), had no  significant effect on leuko- 
cyte responses in mesenteric preparations treated with IL-113 
(n  =  5,  Fig.  1).  Similarly, in two rats pretreated with anti- 
body purified from preimmune serum (5 mg/kg i.v.), leu- 
kocyte responses ehcited by IL-113 were not different from 
those obtained in untreated rats  (data not shown).  In con- 
trast, anti-PECAM-1 Ab (1  or 5  mg/kg i.v.) had no signifi- 
cant effect on the leukocyte responses of rolling and adhesion, 
but  dose  dependently inhibited the  number  of leukocytes 
that had migrated into the tissue (0--50 txm from the venules) 
as compared with rats treated with IL-113 or IL-113 plus con- 
trol Ab  (39  and  72%  inhibition at  1  and  5  mg/kg,  respec- 
tively, Fig. 1 and Fig. 2  C). The leukocyte extravasation de- 
tected in  mesenteric preparations activated with  IL-113  in 
Figure 2.  Video photomicrographs of the effect of the anti-PECAM-1 
Ab on IL-l[3-induced leukocyte extravasation across rat mesenteric mi- 
crovessels. (A) Responses in an animal treated intraperitoneally with sa- 
line; (B) responses in an animal pretreated with control Ab (rabbit IgG, 
5 mg/kg i.v.) before administration of IL-l[3 (10 ng i.p.), clearly showing 
a large number ofleukocytes both intravascular  and extravascular;  and (C) 
responses in an animal pretreated with anti-PECAM-1 Ab (5 mg/kg i.v.) 
before the administration of IL-l[3 (10 ng i.p.) where a layer ofleukocytes 
can be seer~ along the length of the vessel  wall. Scale  bar, 50 Ixm. 
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Figure  3.  Effect  of  anti-PECAM-1 
Ab  on leukocyte  extravasation  induced 
by  IL-113.  Animals  were  treated  with 
control Ab (rabbit  IgG, 5 mg/kg i.v.)  or 
anti-PECAM-1  Ab  (1  or 5 mg/kg i.v.) 
15  min  before  the  intraperitoneal  ad- 
ministration of IL-113.4  h later,  the me- 
senteric  tissue was exteriorized and leu- 
kocyte  extravasation,  at  distances  of 
0-50,  50-100,  and  100-150  Ixm away 
from the vessel wall, across 100-1xm ves- 
sel  segments,  quantified.  Results  are 
mean +  SEM for n =  5 animals.  A sig- 
nificant  difference  between  IL-113  + 
control Ab and IL-113 +  anti-PECAM- 
1 Ab is shown by (*)P <0.05. 
anti-PECAM-1  Ab (5  mg/kg)-treated  rats was not statisti- 
cally different from the small level of extravasation detected 
in  rats  injected  intraperitoneally  with  saline.  Further,  the 
inhibitory  effect of the  anti-PECAM-1  Ab  (5  mg/kg i.v.) 
on leukocyte  extravasation was evident at all measurement 
points from the vessel wall (Fig. 3). An anti-rat MHC  class 
I  mAb,  binding  to  both  leukocytes  and  endothelial  cells, 
had  no  effect  on  the  leukocyte  extravasation  induced  by 
IL-113, i.e., the leukocyte extravasation responses were 8.2  + 
0.8  (n  =  5 rats) and 7.2  +  0.4  (n  =  3  rats) for rats treated 
with IL-113 or IL-I[~ plus anti-MHC class I mAb (5 mg/kg 
i.v.),  respectively.  There  was no  significant  difference  be- 
tween  the  circulating  leukocyte  numbers  in  animals  pre- 
treated  with  the  control  Abs  or  the  anti-PECAM-1  Ab 
(data not shown). 
In  rats  treated  with  the  anti-PECAM-1  Ab,  very  fre- 
quently  a layer of leukocytes was observed adjacent  to the 
vessel wall (Fig. 2  C). Many of these leukocytes did not ap- 
pear to be within the vascular lumen but appeared to have 
migrated out of the vessel, possibly coming to a halt within 
the vessel wall. These leukocytes could not be counted ac- 
curately.  Further,  it  is  important  to  note  that  these  cells 
were not counted as adherent or extravasated, these param- 
eters being limited to cells that were clearly intravascular or 
extravascular,  respectively.  Electron  microscopy  was  used 
to localize these leukocytes. 
Investigation of IL-1[3-activated  Mesenteric Tissues by Elec- 
tron Microscopy.  In control Ab-treated  rats  (5  mg/kg i.v.), 
in venules within sections taken from IL-l[3-activated me- 
senteric  tissues, leukocytes could be seen at different stages 
of their  emigration  from  the  vascular  lumen  to  the  ex- 
travascular tissue  (Fig.  4  A).  In addition  to leukocytes  ap- 
parently  adherent  to the  luminal  side  of the  endothelium, 
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the  sections showed leukocytes that had crossed the  endo- 
thelial  cell  layer  to  the  abluminal  side.  These  leukocytes 
had a rounded morphology and appeared to be in the pro- 
cess  of migrating  through  the  basement membrane.  Elec- 
tron  micrographs  of sections  from IL-l[~-activated mesen- 
teric  tissue,  from  rats  pretreated  with  the  anti-PECAM-1 
Ab (5 mg/kg i.v.), also showed leukocytes that appeared to 
be  in  close  contact with  the  luminal  side  of the  endothe- 
lium (Fig.  4  B).  However, in contrast to the sections from 
animals  treated  with  the  control  Ab,  there  was  a  striking 
accumulation  of leukocytes between  the  endothelium  and 
the  perivascular  basement  membrane  (Fig.  4  B).  The  en- 
trapment  of leukocytes between  the  endothelium  and  the 
perivascular basement membrane is very clearly seen in Fig. 
4  C. In 12 random vessel sections prepared from three con- 
trol  Ab  (rabbit  IgG)-pretreated  rats  (where  a  total  of 439 
leukocytes were  counted),  of the  270  leukocytes  that had 
passed  the  endothelial  cell junctions,  29.1  ---  7.1%  were 
clearly sandwiched between the endothelium  and the base- 
ment  membrane.  In  contrast,  in  15  vessel  sections  from 
four  anti-PECAM-1  Ab-pretreated  rats  (where  a  total  of 
490 leukocytes were counted in all the sections), of the 377 
leukocytes  that had  crossed  the  endothelial  cell junctions, 
57.5  +  3.3%  (P  <0.05)  were  between  the  endothehum 
and  the  basement  membrane  (Fig.  5).  These  leukocytes, 
the  majority of which  had  an  elongated  morphology,  did 
not  appear to be crossing the  basement membrane  so that 
in  some  instances  they  appeared  in  multiple  layers within 
the vessel wall (Fig. 4/3).  In these sections, very few leuko- 
cytes were seen in the extravascular tissue as compared with 
sections from control Ab-treated rats. 
Effect of Anti-PECAM-1  Ab on Leukocyte Extravasation In- 
duced by FMLP.  As we have previously reported  (12),  in Figure 4,  Electron micrographs and corresponding drawings ofmesenteric venules from rats treated with (A, A ') control Ab (rabbit lgG, 5 mg/kg i.v.) 
plus IL-113 (10 ng i.p.)  and (B,  B')  anti-PECAM-1  Ab  (5 mg/kg i.v.) plus IL-113 (10 ng i.p.).  (C)  Part of B at a higher magnification.  In the section 
shown in A, leukocytes can be seen at different stages  of emigration from the vascular lumen to the extravascular tissue, whereas in the section shown in 
B (more clearly seen in C, C') there is a marked accumulation ofleukocytes between the endothehum and the basement membrane. The drawings iden- 
tify the vascular lumen (//), intravascular leukocytes (La), leukocytes between the endothehum and the basement membrane (Lb), a leukocyte crossing the 
basement membrane (Lc), extravascular leukocytes (Ld), leukocyte nuclei (Ln), the endothehal cell barrier (E), an endothelial cell nucleus (En),  perivascu- 
lar basement membrane (BM), a pericyte (/3, and the mesothelium (M). (A)  ￿  (B)  ￿  and (C)  ￿  10,500. 
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Figure  5.  The  effect of the anti-PECAM-1  Ab  on  the percentage  of 
leukocytes trapped between venular endothelial cells and the perivascular 
basement  membrane  in  IL-113-treated  mesenteric  tissues,  as  determined 
by electron microscopy. Rats were treated with a control Ab (rabbit IgG, 
animals  treated intraperitoneally with chemotactic peptide 
FMLP (220 ng for 4 h), the leukocyte responses of  adhesion 
and  extravasation  were  greater  than  the  levels  detected  in 
rats treated  intraperitoneally  with  saline  (results not  shown). 
Pretreatment  of rats with  a  control  antibody  (purified  rabbit 
IgG,  5  mg/kg  i.v.)  or the anti-PECAM-1  Ab  (5 mg/kg  i.v.) 
had  no  effect  on  the  FMLP-induced  leukocyte  adhesion 
(data  not  shown),  or  more  importantly,  FMLP-induced 
leukocyte  extravasation  (Fig.  6). 
5 mg/kg i.v., open column) or the anti-PECAM-1  Ab (5 mg/kg i.v., closed 
column) 15 rain before the i.p. administration of IL-1 ~.  4 h  later, the me- 
senteric tissue was  exteriorized  and tissue sections prepared  for electron 
microscopy. The graph represents the number ofleukocytes observed be- 
tween the venular endothelium and the perivascular basement membrane, 
quantified as the percentage  of the total number of leukocytes  that had 
passed the endothelial cell junctions. The results are from 12-15 sections 
prepared from n  =  3-4 rats within each group. A significant difference is 
shown by (*)P <0.05. 
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saline  control  antibody  anti-PECAM-1 
+  FMLP  i.p.  antibody 
+  FMLP  i.p. 
Effect of the anti-PECAM-1 Ab on leukocyte extravasation 
induced by i.p. FMLP. Rats were treated with saline (i.p., open column), a 
control Ab (rabbit IgG, 5 mg/kg i.v.) plus FMLP (220 ng i.p.; dosed col- 
umn),  or the anti-PECAM-1 Ab (5 mg/kg i.v.) plus FMLP (220 ng i.p.; 
crosshatched column). 4 h later, the mesenteric tissue was exteriorized and 
leukocyte extravasation quantified. R.esults are mean -+ SEM for n =  4 
animals. A significant difference between saline- and IL-l[3-treated rats is 
shown by (*)P <0.05. 
To  investigate the  effect of the  anti-PECAM-1  Ab  on 
rapid responses  elicited by  FMLP,  additional experiments 
were  carried  out  to  test  the  effect  of the  antibody  on 
changes in leukocyte responses after the topical administra- 
tion of FMLP.  In control rats, whereas topical administra- 
tion of FMLP  (final concentration of 10 -7 M) had no sig- 
nificant effect on the number  of rolling leukocytes (results 
not shown), it did cause a rapid increase in leukocyte adhe- 
sion (556% increase above basal levels at 30 rain, n  =  5 rats, 
P  <0.05,  Fig. 7 A) and leukocyte extravasation (395%  in- 
crease above basal levels at 30  rain,  n  =  5  rats,  P  <0.05, 
Fig. 7  B). The responses to topical FMLP were essentially 
complete within 30-45  min  (Fig. 7  and  data not shown). 
Pretreatment  of rats with  a  control Ab (5  mg/kg i.v.),  15 
rain before the topical administration of FMLP, had no sig- 
nificant effect on FMLP-induced leukocyte responses (Fig. 7). 
Similarly, the  anti-PECAM-1  Ab  (5  mg/kg  i.v.)  had  no 
significant  effect  on  FMLP-induced  leukocyte  adhesion, 
and more importantly, had no significant effect on the leu- 
kocyte  extravasation  induced  by  the  topical  chemotactic 
peptide (Fig. 7). 
Interestingly, in mesenteric preparations activated by IL-113 
in  control  Ab-treated  rats,  the  topical  administration  of 
FMLP resulted in a further increase in leukocyte adhesion 
(data not shown) and extravasation above the levels elicited 
by  the  cytokine  (Fig.  8).  In  animals  pretreated  with  the 
anti-PECAM-1  Ab,  although  the  leukocyte  extravasation 
induced by IL-113 was less than that observed in rats treated 
with  the  control Ab,  the  topical administration of FMLP 
stimulated the  leukocytes  that  had  come  to  a  halt  at  the 
vessel wall to migrate into the  extravascular tissue  (Figs. 8 
and  9).  Thus  it would appear that,  in the presence  of the 
anti-PECAM-1  Ab, FMLP could induce the migration of 
the arrested leukocytes through the basement membrane. 
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Figure 7.  Effect  of the anti-PECAM-1 Ab on leukocyte adhesion and 
extravasation induced by topical FMLP. Three  groups of animals were 
used: untreated rats ([~), rats treated with a control Ab (rabbit IgG, 5 mg/ 
kg i.v., []), and rats treated with the anti-PECAM-1 Ab (5 mg/kg i.v., 
k~). The animals were treated with the control Ab or the anti-PECAM-1 
Ab and basal readings of leukocyte adhesion (A) and extravasation (B) re- 
corded. 15 min later, FMLP (at a final concentration of 10 -7 M) was ap- 
plied topically to the preparation and readings taken at 15 and 30 n'fin af- 
ter application. Results are mean +  SEM for n =  4-5 rats. A significant 
difference between baseline values and FMLP-induced responses  is shown 
by (*)P <0.05. 
Discussion 
Previous  studies  have  shown  that  PECAM-1  mediates 
neutrophil  and  monocyte  extravasation through  endothe- 
lial cell monolayers in vitro (9) and anti-PECAM-1 Abs in- 
hibit neutrophil and monocyte  accumulation  into  sites of 
inflammation  in  vivo  (10,  11).  Despite  the  latter studies, 
the stage of emigration at which anti-PECAM-1 antibodies 
inhibit leukocyte accumulation and hence the precise role 
of PECAM-1,  under  dynamic  conditions in vivo, remain 
unclear.  The  aim of the present study was  to  address this 
point, determining at which stage in the migration of leu- 
kocytes from the vascular lumen to the extravascular tissue 
PECAM-1  was  involved.  For this purpose,  intravital mi- 
croscopy was used to visualize directly the effect of an anti- 
body  recognizing  rat  PECAM-1  on  leukocyte  responses 
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Figure 8.  Effect of the anti-PECAM-1 Ab on 
leukocyte extravasation induced by FMLP in IL- 
l~-treated  rats. ILats were pretreated with control 
Ab (rabbit IgG) or anti-PECAM-1 Ab before i.p. 
IL-113.4 h later, the mesenteric  tissue was exterior- 
ized and leukocyte extravasadon 30 rain after the 
topical administration  of Tyrode (open columns) or 
FMLP (I0-7M;  dashed columns) quantified. Re- 
sponses are mean -  SEM for n = 3 animals.  A sig- 
nificant difference between the leukocyte extrava- 
sation after topical Tyrode and FMLP is shown by 
(*)V <0.05. 
within activated rat mesenteric microvessels in vivo. In ad- 
dition, electron microscopy was used to determine the site 
of the inhibitory effect of the anti-PECAM-1 Ab. This Ab, 
which has been well characterized and shown to function 
as  both  intact  IgG  and  as  Fab  fragments,  has  previously 
been shown to inhibit neutrophil accumulation into sites of 
acute  inflammation in rat  peritoneum and rat  lungs, and 
into human skin grafts on immunodeficient  mice (10). 
In control rats, the i.p. injection of recombinant rat IL-113, 
4  h  before the exteriorization of the mesenteric tissue, in- 
duced an inflammatory response that was associated with a 
significant increase in leukocyte rolling and adhesion within 
the  mesenteric venules and  a  large  number of emigrated 
leukocytes in the  extravascular tissue.  Although pretreat- 
ment of rats with an anti-PECAM-1 Ab, but not control 
Abs,  had  no  effect  on  the  IL-113-induced leukocyte  re- 
sponses of rolling and adhesion, it significantly  inhibited the 
leukocyte extravasation elicited by the cytokine. The effect 
of the anti-PECAM-1 Ab was dose dependent, resulting in 
39 and 72% inhibition of extravasation at 1 and 5 mg/kg of 
the Ab, respectively. These results, showing a role for PE- 
CAM-1  in IL-113-induced leukocyte extravasation by di- 
rect observation in vivo, provide a mechanistic explanation 
for the inhibitory effect of anti-PECAM-1 Abs on leuko- 
cyte extravasation into sites of inflammation (10, 11). 
In animals receiving the anti-PECAM-1 Ab, the inhibition 
Figure  9.  Video photomicrographs showing the 
effect of the anti-PECAM-1 Ab on leukocyte ex- 
travasation induced by FMLP in IL-113-treated rats. 
For experimental  details, see legend to Fig. 8. Briefly, 
rats were treated with the anti-PECAM-1 Ab before 
intraperitoneal IL-113 and 4 h later, the mesenteric 
tissue was exteriorized. The photos show responses 
before (A) and 30 min after (/3) the topical adminis- 
tration of FMLP (10  -7 M). Scale bar, 50 Ixm. 
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of venular walls,  which resembled a "wall of leukocytes" 
lining the length of vessel segments in the live microcircu- 
lation (Fig.  2  C). This finding is similar to the histological 
results ofBogen et al. (11) showing an increase in the num- 
ber of leukocytes lining the length of mesenteric venular 
walls in anti-PECAM-l-treated mice. In the study of Bo- 
gen et al.  (11),  these leukocytes appeared retained within 
the vessels. In our study, in order to determine the precise 
site at which the leukocytes had come to a halt at the vessel 
wall,  we  used  electron microscopy to  analyze mesenteric 
tissues  from anti-PECAM-1  Ab-treated rats.  To our sur- 
prise, detailed analysis of numerous sections, obtained from 
several rats,  indicated that within these animals the leuko- 
cytes had migrated through venular endothelial cell junc- 
tions,  but  not  the  perivascular basement  membrane,  and 
were thus trapped within the vessel wall. These leukocytes 
did not appear to be able to cross the basement membrane, 
resulting in the formation of multiple layers of leukocytes 
between  the  endothehal  cell barrier  and  the  perivascular 
basement membrane in some vessel segments. 
Although early in vitro studies demonstrated a role for 
PECAM-1  in  monocyte and  neutrophil  transendothelial 
cell  migration  through  unstimulated  and  TNF-oe-stimu- 
lated endothelial ceil monolayers (9),  recently, PECAM-1 
has  also  been  implicated  in  leukocyte  interactions  with 
components  of the basement membrane  (13).  Liao  et al. 
(13) showed that mAbs whose epitopes mapped to Ig do- 
mains  1-2 of the PECAM-1  molecule selectively blocked 
monocyte migration through unstimulated cultured endo- 
thehal ceils in vitro, whereas mAbs recognizing domain 6 of 
the molecule inhibited the penetration of monocytes into 
the underlying collagen gel. Thus, the antibody used in our 
in vivo studies  may be predominantly directed against  Ig 
domain 6 of PECAM-1. Based on in vitro studies, in addi- 
tion to PECAM-1,  a number of other adhesion molecules 
have also been implicated in the process of IL-l-induced 
leukocyte extravasation (14). Although neutrophil migration 
through IL-l-activated endothehal cell monolayers appears 
to rely heavily on ICAM-1  (15),  E-selectin, has  also been 
implicated in  this response  (16).  ICAM-1,  E-selectin and 
VCAM-1  all appear to have roles in lymphocyte and eosi- 
nophil migration  (17,  18).  The relative contribution and 
precise role of these molecules in leukocyte extravasation 
in vivo remains to be determined. In addition to adhesion 
molecules, it is now clear that certain endothelial cell asso- 
ciated  chemoattractants,  such  as  platelet-activating factor 
(PAF)  and IL-8, are also involved in the passage of neutro- 
phils through IL-l-activated endothelial ceils in vitro (19, 
20).  In support of these findings, we have recently shown 
that PAF receptor antagonists can selectively block the ex- 
travasation  of leukocytes through  IL-l-activated rat  me- 
senteric microvessels in vivo (12).  These observations can 
also  explain the finding that pretreatment of 111In-neutro- 
phils with pertussis  toxin to uncouple receptors, in addition 
to  inhibiting  the  accumulation  induced  by  chemoattrac- 
tants such as  FMLP,  inhibited the  accumulation of 111In- 
neutrophils in response to intradermal IL-1 in rabbits (21). 
237  Wakelin et al. 
In  these  experiments,  pertussis  toxin  may have  inhibited 
the  neutrophil accumulation induced by IL-1  by uncou- 
pling the leukocyte PAF  receptors. Interestingly, whereas 
PAF receptor antagonists and the anti-PECAM-1 Ab both 
inhibited IL-16-induced leukocyte extravasation, there ap- 
peared to be one important difference in the profile of their 
inhibitory effects. In rats pretreated with PAF receptor an- 
tagonists,  the  leukocytes  appeared  to  remain  within  the 
vascular lumen, whereas in animals pretreated with the anti- 
PECAM-1 Ab, the leukocytes appeared trapped in the ves- 
sel wall. 
The in vitro studies ofLiao et al. (13) and our in vivo re- 
sults implicate a functional role for PECAM-1  in the pas- 
sage ofleukocytes through the basement membrane. How- 
ever,  the  mechanism by which  this  occurs is  unclear.  A 
possible explanation is that an important role of PECAM-1 
in vivo is as a molecule triggering leukocyte activation. It 
may be that the hgation of PECAM-1, via domain 6 of the 
Ig molecule, is  involved in the local activation of leuko- 
cytes at endothelial cell junctions, resulting in the stimula- 
tion of other mechanisms that enable the leukocytes to in- 
teract with  and  penetrate  the  basement  membrane.  This 
may  involve  both  adhesive  interaction  with  basement 
membrane components and proteolytic degradation by sur- 
face-expressed enzymes on the leukocytes. Indeed, there is 
now much in vitro evidence indicating that PECAM-1, as 
well as acting as an adhesion molecule, can act as a receptor 
capable of triggering leukocyte activation. In this context, 
PECAM-l-dependent interactions can activate both 61 and 
62 integrins on leukocytes or integrin-expressing COS cells 
(22-25). A  PECAM-l-dependent activation of 61 and 62 
integrins  may  facilitate  both  the  passage  of leukocytes 
through endothelial ceil junctions and their interaction with 
basement membrane components. In contrast to the wen- 
established role of 62 integrins in neutrophil migration in 
vivo (1,  14), there is as yet no in vivo evidence for the in- 
volvement of 61  integrins  in  this  response.  However, in 
vitro studies have shown that 61 integrins can be induced 
on the surface of transmigrating neutrophils (26),  and that 
61 integrins can mediate the interaction of neutrophils with 
components  of the  basement  membrane  such  as  laminin 
(27,  28).  In addition to  endothelial ceils  and extracellular 
matrix proteins, pericytes may also play a role in regulating 
the passage  of leukocytes through the vessel wall.  In most 
of the  tissue  sections  analyzed  by  electron  microscopy, 
pericytes could be seen in the vessel wall embedded within 
the basement membrane (Fig. 4). Hence, an alternative ex- 
planation of our results is that PECAM-1 may be involved in 
the interaction of leukocytes with microvascular pericytes. 
Although the cascade of intermolecular interactions me- 
diating  the  passage  of leukocytes through  IL-l-activated 
endothelial cells is yet to be fully understood, sequential ac- 
tivation of leukocytes may be  critically important in  this 
process. Hughes et al. (29) have presented evidence show- 
ing that increments in chemotactic stimuli are required to 
bring  CD11b/CD18  to  the  surface  of neutrophils  (from 
granules), and that this newly mobilized CD11b/CD18  is 
necessary for adherence-dependent neutrophil  migration. This concept ofa stepwise increase in neutrophil activation 
agrees well with our observations indicating roles for both 
PAF and PECAM-1 in leukocyte extravasation. A possible 
explanation  of our  findings  may  involve  a  sequence  of 
events such as the following:  (a) stimulation of endothelial 
cells by IL-1 results in the upregulation or activation ofse- 
lectins  and  generation  of PAF  which  remains  predomi- 
nantly  endothelial  cell  associated;  (b)  tethering  of leuko- 
cytes to the endothelium by selectins allows an interaction 
between  the  endothelial  cell-associated PAF  and the leu- 
kocyte's cell surface PAF receptors;  (c)  stimulation of leu- 
kocytes by PAF triggers a partial activation of leukocyte 132 
integrins stimulating the firm adhesion and transendothelial 
cell  migration  of  the  leukocytes,  a  response  involving 
ICAM-1,  PECAM-1  (domains  1-2),  as well  as  other in- 
duced  endothelial  cell adhesion  molecules;  and  (d)  at  the 
endothelial cell junctions,  the additional interaction of the 
leukocytes with  endothelial  cell  PECAM-1  (through  do- 
main 6)  triggers further activation of leukocyte 61 and 132 
integrins and release of granular proteases aiding the passage 
of leukocytes across the perivascular basement membrane. 
Hence,  in  animals treated with  PAF  receptor antagonists, 
leukocyte extravasation may have been blocked by inhibit- 
ing the passage of leukocytes into the interendothelial  cell 
junctions, thus forcing the leukocytes to remain within the 
vasculature.  In contrast,  in  animals treated  with  the  anti- 
PECAM-1  Ab  (possibly predominantly directed against Ig 
domain 6), once the leukocytes had entered the endothelial 
cell junctions, the Ab may have prevented the PECAM-1- 
dependent  activation of leukocyte integrins  that  mediates 
and indeed propagates the passage of leukocytes across the 
basement membrane, thus maintaining the leukocytes within 
the vessel wall. This proposal is currently under further in- 
vestigation. 
The  above proposal is  further  supported  by our find- 
ings that both PAF receptor antagonists  (12)  and the anti- 
PECAM-1  Ab  had  no  effect on  the  rapid  leukocyte  ex- 
travasation  induced  by  the  chemotactic  peptide  FMLP. 
One clear difference between the responses elicited by the 
cytokine and  the  chemotactic formyl peptide  is  that pre- 
sumably the extravasation induced by FMLP is as a result of 
direct leukocyte activation and is not dependent on endo- 
thelial cell stimulation.  Thus, leukocyte activation via en- 
dothelial cell-associated PAF or PECAM-1  is not required 
for the  FMLP-induced  leukocyte  extravasation.  It is  im- 
portant to note that FMLP was able to induce the rapid mi- 
gration through the basement membrane of the leukocytes 
held up by anti-PECAM-1  Ab in the  IL-lf3-treated me- 
sentery (Fig.  8).  These results,  which  clearly show that in 
the  same  animal  the  anti-PECAM-1  Ab  inhibits  the  ex- 
travasation induced by IL-113 but not FMLP, further dem- 
onstrate that (a) the inhibitory effect of the anti-PECAM-1 
Ab on leukocyte extravasation was specific to the response 
induced by certain stimuli including IL-113, and (b) the an- 
tibody did not have a nonspecific inhibitory effect on the 
leukocytes. It has also been shown that anti-PECAM-1 Abs 
and soluble PECAM-1 do not affect chemoattractant-induced 
neutrophil or monocyte chemotaxis in vitro (9,  10).  Finally, 
in agreement with our previous findings  (21),  our present 
studies  with  FMLP  and  IL-1  also  indicated  the  apparent 
difference in the potency of these stimuli in eliciting neu- 
trophil accumulation in vivo. Even though  FMLP  had to 
be used at an ~20-fold-greater dose than IL-113 in order to 
induce leukocyte extravasation, the level of FMLP-induced 
response was smaller than that observed with the cytokine, 
suggesting that the difference in the profile of effects seen 
with the anti-PECAM-1  Ab on the two stimuli is unlikely 
to be due to the difference in their respective doses. 
Full  details of the mechanisms mediating the passage of 
leukocytes across venular walls are still unknown. However, 
our results provide the  first direct  evidence for a  role  for 
PECAM-1  in leukocyte extravasation across venules acti- 
vated  by IL-113,  but  not  FMLP,  in  vivo.  These  findings 
demonstrate a differential requirement for PECAM-1 in the 
recruitment  of leukocytes in response to  different inflam- 
matory stimuli and strongly implicate PECAM-1 in the pas- 
sage ofleukocytes across the basement membrane in vivo. 
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